Search Results

Displaying Results 1-7 of 7 "'INTR'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
Endometriosis Imaging Study Published in The Lancet Obstetrics, Gynaecology & Women's Health Highlights 99mTc-maraciclatide as a Promising Diagnostic and Monitoring Tool

Apr 30, 2026, 08:01 ET Endometriosis Imaging Study Published in The Lancet Obstetrics, Gynaecology & Women's Health Highlights 99mTc-maraciclatide as a Promising Diagnostic and Monitoring Tool

here: https://clinicaltrials.gov/study/NCT05623332?intr=NC100692&rank=4Maraciclatide is for investigational use only and is not approved by the FDA or UK and European regulatory

More news about: Serac Healthcare Limited

Mar 09, 2026, 08:00 ET AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

https://clinicaltrials.gov/study/NCT06144684?intr=GUB014295&rank=1#participation-criteria.  Accessed March 3, 2026.Contacts:

More news about: AbbVie

Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer

Oct 19, 2025, 10:30 ET Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer

https://www.clinicaltrials.gov/study/NCT06532032?term=Swallowtail&intr=amivantamab&rank=1. Accessed October 2025.

More news about: Johnson & Johnson

TREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis

Oct 07, 2025, 08:05 ET TREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis

https://clinicaltrials.gov/study/NCT05528510?term=astro&intr=guselkumab&rank=1. Accessed March 2025.9 Crohn's & Colitis Foundation. What is ulcerative colitis? Available

More news about: Johnson & Johnson

Oct 02, 2025, 03:23 ET Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025

https://clinicaltrials.gov/study/NCT06706622?intr=Lu%20AF82422&rank=2 Palma JA, et al. Auton Neurosci. 2018;211:15–25

More news about: H. Lundbeck A/S

Oct 02, 2025, 03:20 ET Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025

https://clinicaltrials.gov/study/NCT06706622?intr=Lu%20AF82422&rank=2 Palma JA, et al. Auton Neurosci. 2018;211:15–25

More news about: H. Lundbeck A/S

TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen

Sep 19, 2025, 17:28 ET TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen

https://clinicaltrials.gov/study/NCT05528510?term=astro&intr=guselkumab&rank=1. Accessed September 2025. 8 National Institutes of Health:

More news about: Johnson & Johnson

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.